Dynavax Technologies (NASDAQ:DVAX) Raised to “Buy” at StockNews.com

Dynavax Technologies (NASDAQ:DVAX) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

Separately, HC Wainwright boosted their target price on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $12.48 on Tuesday. The stock has a market capitalization of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The business has a 50-day moving average of $12.77 and a two-hundred day moving average of $11.66. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in DVAX. GAMMA Investing LLC boosted its stake in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP bought a new position in Dynavax Technologies during the third quarter worth $45,000. Nisa Investment Advisors LLC increased its position in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies during the 3rd quarter valued at $89,000. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.